Quest Diagnostics Q1 Revenue Up, Stock Gains

Quest Diagnostics reported first-quarter 2025 financial results with revenue rising 12.1% year-over-year to $2.65 billion, primarily driven by acquisitions and advanced diagnostics. Adjusted diluted earnings per share grew 18.3% to $2.21, exceeding analyst estimates. Net income reached $220 million, up from $194 million a year earlier, and cash from operations more than doubled to $314 million, signaling operational improvements. Total requisition volume rose 12.4%, while organic requisition volume declined by 0.9%, indicating growth was largely acquisition-driven. The company maintained its full-year 2025 guidance despite a slow start to the year, citing a rebound in demand later in the quarter. Quest's stock price rose in premarket trading following the results announcement, and management reported strong financial health metrics.